

Prof. AZMİ YERLİKAYA

Personal Information

Email: azmi.yerlikaya@ksbu.edu.tr

Web: <https://avesis.ksbu.edu.tr/azmi.yerlikaya>

Address: Kütahya Sağlık Bilimleri Üniversitesi Tıp Fakültesi Tıbbi Biyoloji ABD Evliya Çelebi Yerleşkesi Tavşanlı Yolu 10. Km Kütahya, Türkiye

International Researcher IDs

ORCID: 0000-0002-0678-0701

Publons / Web Of Science ResearcherID: AAS-9289-2020

ScopusID: 55934624100

Yoksis Researcher ID: 119104

Biography

Dr. Azmi Yerlikaya graduated from the Department of Biology, Science Faculty of Hacettepe University in 1990. In 1996, he received his M.Sc. degree from Drexel University, Philadelphia, USA. He obtained his Ph.D. degree from Hershey Medical Center of Pennsylvania State University in 2002. During Ph.D. studies, he worked on the degradation mechanisms of a short-lived protein S-adenosylmethionine decarboxylase, a polyamine biosynthetic enzyme. He currently works at the Faculty of Medicine, Department of Medical Biology, Kütahya Health Sciences University, Turkey. Dr. Yerlikaya carries out research in cancer biology and molecular biology. One of his current research is focused on the development of proteasome inhibitors-resistant cell lines.

Education Information

Doctorate, Pennsylvania State University, Cellular And Molecular Physiology, United States Of America 1997 - 2002

Postgraduate, Drexel University, Art and Science, Bioscience and Biotechnology, United States Of America 1994 - 1996

Undergraduate, Hacettepe University, Fen Fakültesi, Biyoloji Bölümü, Turkey 1986 - 1990

Foreign Languages

English, C1 Advanced

Certificates, Courses and Trainings

Project Management, Proje Yürütücüleri Proje Yönetimi, Proje yöntemi ile ilgili bilimsel ve mali konular, TÜSSİDE, TÜBİTAK, 2006

IT, Microsoft Word version 2002, Microsoft Word program kullanımı sertifikası, Kütahya Dumlupınar Üniversitesi, 2005

Dissertations

Doctorate, Mechanism of S-Adenosylmethionine Decarboxylase Degradation and Changes in Substrate SAM Level Following Inhibition of the 26S Proteasome, Pennsylvania State University, Cellular And Molecular Physiology, 2002

Research Areas

Health Sciences, Natural Sciences

Academic Titles / Tasks

Professor, Kütahya Health Sciences University, Tıp Fakültesi, Temel Tıp Bilimleri, 2018 - Continues

Professor, Kütahya Dumlupınar University, School Of Medicine, 2016 - 2018

Associate Professor, Dumlupınar Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, 2013 - 2016

Associate Professor, Dumlupınar Üniversitesi, Fen-Edebiyat Fakültesi, Biyoloji Bölümü, 2010 - 2013

Assistant Professor, Dumlupınar Üniversitesi, Fen-Edebiyat Fakültesi, Biyoloji Bölümü, 2004 - 2010

Academic and Administrative Experience

Head of Department, Kütahya Health Sciences University, Tıp Fakültesi, Temel Tıp Bilimleri, 2024 - Continues

Head of Department, Kütahya Health Sciences University, Tıp Fakültesi, Dahili Tıp Bilimleri, 2023 - Continues

Fakülte Yönetim Kurulu Üyesi, Kütahya Health Sciences University, Diş Hekimliği Fakültesi, 2021 - Continues

University Executive Board Member, Kütahya Health Sciences University, Tıp Fakültesi, Temel Tıp Bilimleri, 2018 - 2022

Head of Department, Kütahya Health Sciences University, Tıp Fakültesi, Temel Tıp Bilimleri, 2016 - 2021

Head of Department, Kütahya Health Sciences University, Tıp Fakültesi, Temel Tıp Bilimleri, 2016 - 2021

Head of Department, Kütahya Dumlupınar University, School Of Medicine, 2013 - 2018

Deputy Head of Department, Kütahya Dumlupınar University, Faculty Of Arts And Sciences, 2004 - 2013

Advising Theses

YERLİKAYA A., Proteozom inhibitörü bortezomib ve cisplatin'nin 4t1 kanser hücrelerindeki etkileri, Postgraduate, R.UZUN(Student), 2018

YERLİKAYA A., Bortezomib ve BAPTA kombinasyonun 4T1 fare meme kanseri hücrelerinde çeşitli sinyal iletim yolları üzerindeki etkisi, Postgraduate, Ş.YERLİKAYA(Student), 2016

YERLİKAYA A., Prokaryotlarda ubiquitin benzeri proteinlerin biyoinformatik yöntemlerle belirlenmesi, Postgraduate, E.ŞENOL(Student), 2015

YERLİKAYA A., GRP78 inhibitörü bapta ve velcade kombinasyonunun 4T1 hücre kültürü üzerindeki etkilerinin in vitro belirlenmesi, Postgraduate, E.ERDOĞAN(Student), 2014

Yerlikaya A., Canbek M., Siçanlarda parsiyel hepatektomi sonrası karaciğer rejenerasyonuna geraniolün etkisinin NF- κ B yolağı üzerinden belirlenmesi, Doctorate, E.CEYHAN(Student), 2013

YERLİKAYA A., 5-fluorouracil ve proteozom inhibitörü bortezomib'in 4T1 meme kanseri hücrelerindeki etkileri, Postgraduate, F.ZEHRA(Student), 2013

YERLİKAYA A., Proteozom inhibitörü PS-341 ve HSP70 inhibitörü quercetin B16F10 hücre kültürüne etkileri, Postgraduate, S.ŞEKER(Student), 2010

YERLİKAYA A., Proteozom inhibisyonun 4T1 meme ve B16F10 melanoma hücrelerindeki apoptotik etkilerinin araştırılması, Postgraduate, E.OKUR(Student), 2010

YERLİKAYA A., Proteozom inhibitörü MG-132'nin kanser hücre dizilerine etkisi, Postgraduate, H.DOKUDUR(Student), 2009

Jury Memberships

Associate Professor Exam, Associate Professor Exam, İstanbul Üniversitesi-Cerrahpaşa, June, 2023

Appointment to Academic Staff-Professorship, Appointment to Academic Staff-Professorship, Eskişehir Osmangazi

Üniversitesi, July, 2022

Associate Professor Exam, Associate Professor Exam, Kütahya Sağlık Bilimleri Üniversitesi, December, 2021

Appointment to Academic Staff-Assistant Professorship, Appointment to Academic Staff-Assistant Professorship, Sakarya Üniversitesi, October, 2021

Designed Lessons

Yerlikaya A., Drug Design and Development, Doctorate, 2023 - 2024

Published journal articles indexed by SCI, SSCI, and AHCI

- I. **Label-free nLC-MS/MS proteomic analysis reveals significant differences in the proteome between colorectal cancer tissues and normal colon mucosa**
Zeren S., Seker S., Akgün G. A., Okur E., YERLİKAYA A.
Medical Oncology, vol.40, no.10, 2023 (SCI-Expanded)
- II. **The Senescence Program is Reduced in Proteasome Inhibitor Bortezomib-Resistant PC3 Prostate Cancer Cell Line**
Kanbur E., Şeker S., Budak F., Yerlikaya A.
European Journal of Biology, vol.81, no.1, pp.49-58, 2023 (SCI-Expanded)
- III. **Molecular Pathways, Targeted Therapies, and Proteomic Investigations of Colorectal Cancer.**
Yerlikaya A., Zeren S.
Current molecular medicine, vol.23, no.1, pp.2-12, 2023 (SCI-Expanded)
- IV. **Heme-regulated inhibitor: an overlooked eIF2 α kinase in cancer investigations.**
Yerlikaya A.
Medical oncology (Northwood, London, England), vol.39, no.5, pp.73, 2022 (SCI-Expanded)
- V. **Molecular analysis of cell survival and death pathways in the proteasome inhibitor bortezomib-resistant PC3 prostate cancer cell line.**
Kanbur E., Baykal A. T., Yerlikaya A.
Medical oncology (Northwood, London, England), vol.38, pp.112, 2021 (SCI-Expanded)
- VI. **The Ubiquitin-Proteasome Pathway and Epigenetic Modifications in Cancer.**
Yerlikaya A., Kanbur E., Stanley B. A., Tümer E.
Anti-cancer agents in medicinal chemistry, vol.21, pp.20-32, 2021 (SCI-Expanded)
- VII. **An investigation of the mechanisms underlying the proteasome inhibitor bortezomib resistance in PC3 prostate cancer cell line**
Yerlikaya A., Okur E.
CYTOTECHNOLOGY, vol.72, no.1, pp.121-130, 2020 (SCI-Expanded)
- VIII. **The ubiquitin-proteasome pathway and resistance mechanisms developed against the proteasomal inhibitors in cancer cells.**
Yerlikaya A., Kanbur E.
Current drug targets, vol.21, pp.1313-1325, 2020 (SCI-Expanded)
- IX. **A novel and effective inhibitor combination involving bortezomib and OTSSP167 for breast cancer cells in light of label-free proteomic analysis**
Okur E., Yerlikaya A.
CELL BIOLOGY AND TOXICOLOGY, vol.35, no.1, pp.33-47, 2019 (SCI-Expanded)
- X. **Secretomes reveal several novel proteins as well as TGF-beta 1 as the top upstream regulator of metastatic process in breast cancer**
ERİN N., Ogan N., YERLİKAYA A.
BREAST CANCER RESEARCH AND TREATMENT, vol.170, no.2, pp.235-250, 2018 (SCI-Expanded)
- XI. **Differential effects of p38 MAP kinase inhibitors SB203580 and SB202190 on growth and migration**

of human MDA-MB-231 cancer cell line

DÜZGÜN Ş. A., YERLİKAYA A., ZEREN S., BAYHAN Z., OKUR E., BOYACI İ.
CYTOTECHNOLOGY, vol.69, no.4, pp.711-724, 2017 (SCI-Expanded)

- XII. **A novel combination treatment for breast cancer cells involving BAPTA-AM and proteasome inhibitor bortezomib**
YERLİKAYA A., Erdoğan E., OKUR E., Yerlikaya Ş., SAVRAN B.
ONCOLOGY LETTERS, vol.12, no.1, pp.323-330, 2016 (SCI-Expanded)
- XIII. **Bortezomib and etoposide combinations exert synergistic effects on the human prostate cancer cell line PC-3.**
Aras B., Yerlikaya A.
Oncology letters, vol.11, pp.3179-3184, 2016 (SCI-Expanded)
- XIV. **A proteomic analysis of p53-independent induction of apoptosis by bortezomib in 4T1 breast cancer cell line**
YERLİKAYA A., OKUR E., BAYKAL A. T., Acilan C., BOYACI İ., ULUKAYA E.
JOURNAL OF PROTEOMICS, vol.113, pp.315-325, 2015 (SCI-Expanded)
- XV. **Data for a proteomic analysis of p53 independent induction of apoptosis by bortezomib**
YERLİKAYA A., OKUR E., BAYKAL A. T., Acilan C., BOYACI İ., ULUKAYA E.
DATA IN BRIEF, vol.1, pp.56-59, 2014 (SCI-Expanded)
- XVI. **Additive enhancement of apoptosis by TRAIL and fenretinide in metastatic breast cancer cells in vitro**
ULUKAYA E., Sarimahmut M., CEVATEMRE B., Ari F., YERLİKAYA A., Dimas K.
BIOMEDICINE & PHARMACOTHERAPY, vol.68, no.4, pp.477-482, 2014 (SCI-Expanded)
- XVII. **Anticancer Agent Ukrain and Bortezomib Combination is Synergistic in 4T1 Breast Cancer Cells**
SAVRAN B., YERLİKAYA A., Erdoğan E., GENÇ O.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, vol.14, no.3, pp.466-472, 2014 (SCI-Expanded)
- XVIII. **Evaluation of whether the ACE gene I/D polymorphism constitutes a risk factor for chronic obstructive pulmonary disease in the Turkish population**
AYADA C., TORU Ü., GENÇ O., YERLİKAYA A., ŞAHİN S., TURGUT S., TURGUT G.
GENETICS AND MOLECULAR RESEARCH, vol.13, no.4, pp.10427-10433, 2014 (SCI-Expanded)
- XIX. **Evaluation of antiproliferative and antimetastatic effects of heparin and erythropoietin on B16f10 melanoma cell line**
Koçak F. E., Erdoğan E., Özyiğit F., Yerlikaya A.
Cellular And Molecular Biology, vol.59, pp.1894-1898, 2013 (SCI-Expanded)
- XX. **The Significance of Ubiquitin Proteasome Pathway in Cancer Development**
YERLİKAYA A., Yontem M.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY, vol.8, no.3, pp.298-309, 2013 (SCI-Expanded)
- XXI. **Effect of bortezomib in combination with cisplatin and 5-fluorouracil on 4T1 breast cancer cells**
YERLİKAYA A., Altikat S., Irmak R., Cavga F. Z., Kocacan S., BOYACI İ.
MOLECULAR MEDICINE REPORTS, vol.8, no.1, pp.277-281, 2013 (SCI-Expanded)
- XXII. **Expression of Heme Oxygenase-1 in Response to Proteasomal Inhibition**
YERLİKAYA A.
PROTEIN AND PEPTIDE LETTERS, vol.19, no.12, pp.1330-1333, 2012 (SCI-Expanded)
- XXIII. **The p53-independent induction of apoptosis in breast cancer cells in response to proteasome inhibitor bortezomib**
YERLİKAYA A., OKUR E., ULUKAYA E.
TUMOR BIOLOGY, vol.33, no.5, pp.1385-1392, 2012 (SCI-Expanded)
- XXIV. **Investigation of the eIF2 alpha phosphorylation mechanism in response to proteasome inhibition in melanoma and breast cancer cells**
Yerlikaya A., Dokudur H.
MOLECULAR BIOLOGY, vol.44, no.5, pp.760-768, 2010 (SCI-Expanded)
- XXV. **Combined effects of the proteasome inhibitor bortezomib and Hsp70 inhibitors on the B16F10**

melanoma cell line

YERLİKAYA A., OKUR E., Seker S., ERİN N.

MOLECULAR MEDICINE REPORTS, vol.3, no.2, pp.333-339, 2010 (SCI-Expanded)

XXVI. Differential sensitivity of breast cancer and melanoma cells to proteasome inhibitor Velcade

YERLİKAYA A., ERİN N.

INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE, vol.22, no.6, pp.817-823, 2008 (SCI-Expanded)

XXVII. Phosphorylation of eIF2 alpha in response to 26S proteasome inhibition is mediated by the haem-regulated inhibitor (HRI) kinase

YERLİKAYA A., Kimball S., Stanley B. A.

BIOCHEMICAL JOURNAL, vol.412, pp.579-588, 2008 (SCI-Expanded)

XXVIII. Variations in fatty acids composition of pikeperch (Sander lucioperca) liver with respect to gonad maturation

UYSAL K., YERLİKAYA A., Aksoylar M., YÖNTEM M., ULUPINAR M.

ECOLOGY OF FRESHWATER FISH, vol.15, no.4, pp.441-445, 2006 (SCI-Expanded)

XXIX. Structural basis for the inactivation of AdoMetDC K12R mutant

YERLİKAYA A., Stanley B. A.

PROTEIN AND PEPTIDE LETTERS, vol.13, no.3, pp.313-317, 2006 (SCI-Expanded)

XXX. Polyamines and S adenosylmethionine decarboxylase a polyamine biosynthetic enzyme

YERLİKAYA A.

Turkish Journal of Biochemistry, vol.29, pp.208-214, 2004 (SCI-Expanded)

XXXI. S-Adenosylmethionine decarboxylase degradation by the 26 S proteasome is accelerated by substrate-mediated transamination

YERLİKAYA A., Stanley B. A.

JOURNAL OF BIOLOGICAL CHEMISTRY, vol.279, no.13, pp.12469-12478, 2004 (SCI-Expanded)

Articles Published in Other Journals

I. Eksenatidin 3D 3T3-L1 Adipositleri Üzerindeki Ekspresyon Profilinin Mikrodizin Analizi ile Belirlenmesi

Koldemir Gündüz M., Kaymak G., Kanbur E., Berikten D., Şener H., Yerlikaya A.

İğdır Üniversitesi Fen Bilimleri Enstitüsü Dergisi, vol.12, no.4, pp.1995-2003, 2022 (Peer-Reviewed Journal)

II. Proteozom inhibitörü MG132 nin 4T1 meme ve B16F10 melanoma kanser hücrelerindeki sitotoksik etkileri

YERLİKAYA A., Dokudur H., Şeker S.

Dumlupınar Üniversitesi Fen Bilimleri Dergisi, vol.19, pp.15-22, 2009 (Peer-Reviewed Journal)

III. Protein yıkımının önemi

YERLİKAYA A., Dokudur H.

Uludağ Üniversitesi Tıp Fakültesi Dergisi, vol.35, pp.93-99, 2009 (Peer-Reviewed Journal)

IV. Cellular functions of the 26S proteasome

YERLİKAYA A.

Turkish Journal of Biology, vol.28, pp.31-38, 2004 (Peer-Reviewed Journal)

Books & Book Chapters

I. Bölüm G - Beyin

Yerlikaya A.

in: İnsan Fizyolojisi, Addurrahman Aktümsek, Editor, Nobel Yayınevi, Ankara, pp.193-232, 2010

II. Protein sentezi ve yıkımı

YERLİKAYA A.

Refereed Congress / Symposium Publications in Proceedings

- I. **26S Proteozom İnhibitörü Bortezomibe Dirençli Prostat Hücre Hattı ve Direnç Mekanizmaları**
Kanbur E., Tümer E., Budak F., Yerlikaya A.
25. Ulusal İmmünoloji Kongresi, Bursa, Turkey, 20 - 22 November 2020, pp.5-6
- II. **Proteozom inhibitörü carfilzomib'in vinkristin ve karboplatin ile Y79 retinoblastom hücre hattı üzerindeki in vitro etkinliklerinin karşılaştırılması.**
AKTAŞ S., OKUR E., YERLİKAYA A., AKTAŞ H., ÖZCURA F.
TOD 51. Ulusal Oftalmoloji Kongresi, Turkey, 24 - 29 October 2017
- III. **Kanser Araştırmalarında Proteomik Yaklaşımlar, Deneysel Modeller ve Getirileri**
YERLİKAYA A., OKUR E.
24. Ulusal Farmakoloji Kongresi, Turkey, 17 - 20 October 2017
- IV. **Comparisons of metastatic and non-metastatic breast carcinoma cells using proteomic analysis of exosomes reveals increased secretion of BMP-1, fibulin4 and TGF-B1**
Ogan N., YERLİKAYA A., ERİN N.
3rd Congress of the Serbian Association for Cancer Research, Belgrade, Serbia And Montenegro, 6 - 07 October 2017, pp.55-56
- V. **Proteozom İnhibitörü Bortezomibe Dirençli Prostat PC-3 Kanseri Hücresi**
YEŞİLMEN B., YERLİKAYA A., OKUR E.
17. ULUSAL MARMARA ÜNİVERSİTESİ TIP ÖĞRENCİ KONGRESİ, Turkey, 12 - 14 May 2017
- VI. **Increased Expression of TGF 1 and TSLP in Highly Metastatic Breast Cancer Cell Lines**
Yitiz N., YERLİKAYA A., ERİN N.
6. Multidisipliner Kanser Araştırma Kongresi, Konya, Turkey, 27 - 30 October 2016
- VII. **Effects of p38 MAP kinase inhibitors on MDA MB 231 cell line**
DÜZGÜN Ş. A., YERLİKAYA A., ZEREN S., BAYHAN Z., OKUR E.
41st FEBS Congress, 3 - 08 September 2016
- VIII. **Comparisons of metastatic and non metastatic breast carcinoma cells using proteomic analysis of exosomes**
ERİN N., YERLİKAYA A.
41st FEBS Congress, 3 - 08 September 2016
- IX. **The effect of season on liver fatty acids of pikeperch Sander lucioperca from lake Eğirdir Turkey**
UYSAL K., YERLİKAYA A., Aksoylar M., YÖNTEM M., ULUPINAR M.
II: International Natural Protection Symposium, 8 - 10 September 2005
- X. **Apoptotic mechanism of a new combination involving bortezomib and GRP78 inhibitor BAPTA on 4T1 cancer cells**
Yerlikaya Ş., OKUR E., YERLİKAYA A.
3rd Anticancer Agent Development Congress, 18 - 19 May 2015
- XI. **Evaluation of antiproliferative and antimetastatic effects of heparin and erythropoietin on B16F10 melanoma cell line**
KOÇAK F. E., Erdoğan E., Özyiğit F., YERLİKAYA A.
Kongre & Lab Expo 2014, 16 - 20 September 2014
- XII. **The antiproliferation and antitumor activities of the 26S proteasome inhibitors**
YERLİKAYA A., ERİN N.
Joint 4th EORTC Pathobiology Group Annual Meeting & 1st International Multidisciplinary Cancer Research Congress, 21 - 24 May 2009
- XIII. **The 26S proteasome one of the most critical players in cancer development**
YERLİKAYA A.

The EACR-Sponsored 2nd Anticancer Agents Congress: Targeting Cancer Stem Cells, 23 - 25 April 2014

XIV. Additive enhancement of apoptosis by TRAIL and fenretinide in metastatic breast cancer cells in vitro

SARIMAHMUT M., CEVATEMRE B., ARI F., YERLİKAYA A., Dimas K., ULUKAYA E.

The EACR-Sponsored 2nd Anticancer Agents Congress: Targeting Cancer Stem Cells, 23 - 25 April 2014

XV. Targeting the proteasome for the induction of apoptosis in cancer treatment

YERLİKAYA A.

EACR-Anticancer Agents Research Congress, 13 - 16 October 2011

XVI. Effect of proteasome inhibition on protein synthesis and eIF 2 phosphorylation

YERLİKAYA A.

1. Multidisipliner Kanser Araştırma Sempozyumu (uluslararası katılımlı), 12 - 15 March 2006

Supported Projects

YERLİKAYA A., Kanbur E., Project Supported by Higher Education Institutions, Proteozom inhibitörü bortezomibe karşı geliştirilen direnç mekanizmasında tümör baskılayıcı işlevleri olan hücre senesans rolünün ve mekanizmasının araştırılması, 2021 - 2022

Yerlikaya A., Tümer E., TUBITAK Project, Proteozom inhibitörü bortezomibe dirençli PC3 prostat hücrelerinde hücre ölüm modu ve PI3K/MAPK sinyal yollarının araştırılması, 2019 - 2021

Tümer E., Yerlikaya A., TUBITAK Project, Bor içeren yeni sodyum bütirat türevlerinin CaCo-2 kolon ve 4T1 meme hücre hatlarındaki etkileri, 2019 - 2021

Erin N., Yerlikaya A., TUBITAK Project, Investigation of the role of extracellular matrix proteins Fibulin-4 in metastatic breast cancer cells: interaction with TGF- β 1, LTBP-1 and BMP-1, 2018 - 2021

Yerlikaya A., Project Supported by Higher Education Institutions, Proteozom inhibitörü bortezomibe dirençli PC3 prostat kanseri hücre hattı eldesi ve çeşitli antineoplasiklere karşı hassasitenin belirlenmesi, 2017 - 2018

ÖZCURA F., YERLİKAYA A., Project Supported by Higher Education Institutions, Proteozom İnhibitörü Carfilzomib ve Çeşitli Antineoplastiklerin Y79 Retinoblastom Hücre Hattı Üzerindeki in Vitro Etkinlikleri, 2016 - 2017

Yerlikaya A., Ceyhan E., Project Supported by Higher Education Institutions, Sıçanlarda Parsiyel Hepatektomi Sonrası Karaciğer Rejenerasyonuna Lösinin Mapk Erk Yolağı Üzerinden Etkisi, 2014 - 2017

Yerlikaya A., Ulukaya E., TUBITAK Project, Olası Bir Anti Kanser Bileşik Terpiridin İçeren Palladyum II Sakkarinat Kompleksinin Pd Sac Terpy Sac Meme Kanser Kök Hücreleri Üzerindeki Sitotoksik Sitostatik Etkilerinin ve Mekanizmalarının Araştırılması, 2014 - 2016

YERLİKAYA A., TUBITAK Project, Proteozom İnhibitörü Bortezomib Ve Grp78 Bip İnhibitörü Bapta Nın Metastatik 4t1 Meme Kanseri Hücreleri Üzerindeki Kombine Etkisi, 2013 - 2016

Arslan O., Yerlikaya A., TUBITAK Project, Taraxacum officinale karahindiba ve Cornus mas kıvılcık bitkilerinin karşılaştırmalı B16F10 melanoma ve 4T1 meme kanseri hücre kültürlerine etkileri, 2014 - 2015

Arslan F., Yerlikaya A., TUBITAK Project, Muscari miller Arap sümbülü ve Plantago lanceolata sinir otu bitkilerinin karşılaştırmalı B16F10 melanoma ve 4T1 meme kanseri hücre kültürlerine etkileri, 2014 - 2015

YERLİKAYA A., TUBITAK Project, Proteozom inhibitörü Velcadein 4T1 kanser hücrelerinde uyardığı p53 bağımsız apoptozisin araştırılması, 2009 - 2012

YERLİKAYA A., TUBITAK Project, Proteozom inhibisyonunun meme ve melanoma kanser hücre dizileri üzerindeki etkileri, 2006 - 2009

Activities in Scientific Journals

International Journal of Applied Biology and Environmental Sciences (IJABES), Committee Member, 2019 - Continues
Oncology Letters, Committee Member, 2018 - Continues

Memberships / Tasks in Scientific Organizations

European Association for Cancer Research, Member, 2015 - Continues, United Kingdom

Molecular Cancer Research Association, Member, 2011 - Continues

Scientific Refereeing

TURKISH JOURNAL OF BIOLOGY, SCI Journal, May 2024

Project Supported by Higher Education Institutions, BAP Research Project, Bursa Uludağ University, Turkey, May 2024

Online Türk Sağlık Bilimleri Dergisi, National Scientific Refreed Journal, November 2023

Online Türk Sağlık Bilimleri Dergisi, National Scientific Refreed Journal, September 2023

Project Supported by Higher Education Institutions, BAP MSc, Bursa Uludağ University, Turkey, September 2023

ONCOLOGY RESEARCH, SCI Journal, May 2023

TUBITAK Project, 1001 - Program for Supporting Scientific and Technological Research Projects, TÜBİTAK, Turkey, January 2023

Research Project of the Presidency of Turkey Health Institutes (TÜSEB), TÜSEB, Turkey, November 2022

European Journal of Biology, National Scientific Refreed Journal, October 2022

Project Supported by Higher Education Institutions, BAP Research Project, Akdeniz University, Turkey, June 2022

TUBITAK Project, 1001 - Program for Supporting Scientific and Technological Research Projects, TÜBİTAK, Turkey, May 2022

BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, SCI Journal, April 2022

Project Supported by Higher Education Institutions, BAP MSc, Kütahya Health Sciences University, Turkey, April 2022

Project Supported by Higher Education Institutions, BAP Research Project, İstanbul University-Cerrahpaşa, Turkey, February 2022

TUBITAK Project, 1001 - Program for Supporting Scientific and Technological Research Projects, Kütahya Health Sciences University, Turkey, September 2021

TUBITAK Project, 1001 - Program for Supporting Scientific and Technological Research Projects, Kütahya Health Sciences University, Turkey, March 2021

ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, SCI Journal, August 2020

Health Sciences Journal of Adiyaman University, National Scientific Refreed Journal, July 2020

Journal Of Agriculture and Nature, National Scientific Refreed Journal, July 2020

Project Supported by Higher Education Institutions, BAP Research Project, Kütahya Health Sciences University, Turkey, February 2020

Experimental And Therapeutic Medicine, SCI Journal, January 2019

ONCOLOGY LETTERS, SCI Journal, March 2018

Scientific Consultations

TÜBİTAK, Project Consultancy, Kütahya Health Sciences University, Tıp Fakültesi, Temel Tıp Bilimleri, Turkey, 2021 - 2022

Tasks In Event Organizations

Yerlikaya A., 3rd International Multidisciplinary Cancer Research Congress, Scientific Congress, Bolu, Turkey, Ağustos 2023

Yerlikaya A., 2nd International Multidisciplinary Cancer Research Congress, Scientific Congress, Giresun, Turkey, Temmuz 2022

Metrics

Publication: 55

Citation (WoS): 386

Citation (Scopus): 478

H-Index (WoS): 12

H-Index (Scopus): 12

Invited Talks

Cellular Functions of the 26S Proteasome, Seminar, İhsan Doğramacı Bilkent Üniversitesi, Turkey, October 2009

Scholarships

Yüksek Öğretim Kurumu lisansüstü eğitim bursu, YOK, 1994 - 2002

Awards

Okur E., Yerlikaya A., LAV Kütahya Dumlupınar University Graduate Education Institute Turquoise Achievement Awards, Kütahya Dumlupınar Üniversitesi, May 2022

Yerlikaya A., MOKAD's SPECIAL AWARD, Moleküler Kanser Araştırma Derneği (Mokad), May 2015

Yerlikaya A., MOKAD's SPECIAL AWARD, Moleküler Kanser Araştırma Derneği (Mokad), December 2012